Bausch Health Companies Inc. (NYSE:BHC) Shares Sold by Barclays PLC

Barclays PLC trimmed its holdings in Bausch Health Companies Inc. (NYSE:BHC) by 26.6% in the third quarter, Holdings Channel.com reports. The fund owned 162,772 shares of the company’s stock after selling 59,019 shares during the period. Barclays PLC’s holdings in Bausch Health Companies were worth $1,327,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of BHC. Mackenzie Financial Corp boosted its position in shares of Bausch Health Companies by 111.0% in the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock valued at $16,612,000 after purchasing an additional 1,252,834 shares during the period. LMR Partners LLP acquired a new stake in Bausch Health Companies during the 3rd quarter worth about $3,264,000. Clearline Capital LP purchased a new stake in Bausch Health Companies during the second quarter valued at about $6,881,000. Intact Investment Management Inc. acquired a new position in shares of Bausch Health Companies in the third quarter worth about $1,543,000. Finally, XTX Topco Ltd purchased a new position in shares of Bausch Health Companies in the third quarter worth approximately $938,000. 78.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BHC has been the subject of a number of research reports. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Friday, October 25th. Evercore ISI upgraded shares of Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. Finally, Royal Bank of Canada increased their target price on shares of Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $7.75.

Bausch Health Companies Stock Up 0.5 %

Shares of BHC stock opened at $7.65 on Friday. The business’s 50 day moving average is $8.25 and its two-hundred day moving average is $7.32. Bausch Health Companies Inc. has a 12 month low of $3.96 and a 12 month high of $11.46. The company has a market cap of $2.77 billion, a PE ratio of -15.94 and a beta of 0.69.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The business had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same period in the previous year, the company posted $1.03 earnings per share. The firm’s revenue for the quarter was up 12.2% on a year-over-year basis. As a group, equities analysts expect that Bausch Health Companies Inc. will post 3.74 EPS for the current fiscal year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.